Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015		Sep. 30, 2014
Cash flows from operating activities
Net loss	$ (129,843)		$ (320,492)
Adjustments to reconcile net loss to net cash provided by (used in) provided by operating activities:
Depreciation and amortization	67,290		65,272
Deferred rent expense	153		477
Deferred income taxes	(773)		638
Stock-based compensation	6		99
Provision for doubtful accounts	13,872		13,345
(Gain) loss on the sale/disposal of property and equipment	(143)		256
Loss on sale leaseback transaction			135
Gain on the sale of marketable securities	(2)
Impairment loss			229,526
Early extinguishment of debt	37,390		8,558
Equity initial public offering expenses			4,905
Loss on foreign currency transactions	298		105
Gain on foreign currency derivative contracts			(4)
Fair value adjustment of noncontrolling interest and earn-out liabilities	(518)		612
Fair value adjustment of embedded derivatives and other financial instruments	8,922
Amortization of debt discount	1,228		2,035
Amortization of loan costs	3,675		4,821
Paid in kind interest on notes payable	370
Equity interest in net (earnings) loss of joint ventures	(202)		161
Distribution received from unconsolidated joint ventures	106		168
Changes in operating assets and liabilities:
Accounts receivable and other current assets	(33,058)		(31,317)
Income taxes payable	(109)		(933)
Inventories	(624)		(195)
Prepaid expenses	2,192		2,747
Accounts payable	3,921		12,320
Accrued deferred compensation	1,057		1,059
Accrued expenses / other liabilities	58,134		17,392
Net cash provided by operating activities	33,342		11,690
Cash flows from investing activities
Purchase of property and equipment	(33,595)		(44,269)
Acquisition of medical practices	(33,064)		(50,121)
Restricted cash associated with medical practice acquisitions	6,970		(3,471)
Proceeds from the sale of property and equipment	1,143		91
Purchase of marketable securities	(4,633)
Sale of marketable securities	4,013
Repayments from (loans to) employees	353		(871)
Contribution of capital to joint venture entities			(620)
Distribution received from joint venture entities	496
Proceeds from foreign currency derivative contracts			26
Company owned life insurance policies	(1,015)		(851)
Change in other assets and other liabilities	45		(256)
Net cash used in investing activities	(59,287)		(100,342)
Cash flows from financing activities
Proceeds from issuance of debt (net of original issue discount of $6.1 million and $3.4 million, respectively)	972,851		164,556
Principal repayments of debt	(921,871)		(250,208)
Repayments of finance obligation	(168)		(167)
Proceeds from issuance of Series A convertible redeemable preferred stock			325,000
Proceeds from issuance of noncontrolling interest	743		1,250
Proceeds from noncontrolling interest holders - redeemable and non-redeemable	3,230		229
Purchase of noncontrolling interest - non-redeemable	(16,233)
Cash distributions to noncontrolling interest holders - redeemable and non-redeemable	(4,072)		(2,050)
Payments for contingent considerations	(8,537)
Payments of costs for equity securities offering			(4,220)
Payment of call premium on long-term debt	(24,877)
Payments of loan costs	(26,481)		(2,437)
Net cash (used in) provided by financing activities	(25,415)		231,953
Effect of exchange rate changes on cash and cash equivalents	(14)		(42)
Net (decrease) increase in cash and cash equivalents	(51,374)		143,259
Cash and cash equivalents, beginning of period	99,167	[1]	17,462
Cash and cash equivalents, end of period	47,793		160,721
Supplemental disclosure of non-cash investing and financing activities
Finance obligation related to real estate projects	844		2,465
Derecognition of finance obligation related to real estate projects	12,215		4,119
Capital lease obligations related to the purchase of equipment	2,408		7,069
Medical equipment and service contract component related to the acquisition of medical equipment through accounts payable	665		12,486
Issuance of notes payable relating to the acquisition of medical practices			2,000
Liability relating to the escrow debt and purchase price of medical practices			2,970
Capital lease obligations related to the acquisition of medical practices			47,796
Change in earn-out liabilities	13,572		1,003
Assumed debt obligations related to the acquisition of medical practices	290
Amounts payable to sellers in the purchase of a medical practice	150		295
Incurred offering costs			685
Noncash dividend declared to noncontrolling interest	35		246
Noncash issuance of noncontrolling interest	56
Issuance costs related to the Series A convertible preferred stock			6,792
Issuance of notes payable relating to the purchase of SFRO noncontrolling interest	14,560
Issuance of equity units relating to the purchase of SFRO noncontrolling interest	14,500
Accrued dividends on Series A convertible preferred stock, accrued at effective rate	29,828		982
Accretion of redemption value on Series A convertible preferred stock	14,728		$ 87
Change in additional paid-in capital from sale/purchase of interest in subsidiaries	$ 3,780

[1] Derived from audited financial statements.